読み込み中
NASDAQHealthcareMedical - Diagnostics & Research
最新データ
$15.00
$0.00 · -0.67%
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
終値時点
$15.00
$0.00 · -0.67%
時間外
$15.00
$0.00 · 0.00%
10月13日 16:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
日中レンジ
現在 $15.00
52週レンジ
現在 $15.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
59
適正価値
センチメント
52
まちまち
リスク
74
高リスク
モメンタム
28
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
日中レンジ
現在 $15.00
52週レンジ
現在 $15.00
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CNY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5.4億 CNY | 5.16億 CNY | 5.37億 CNY | 5.63億 CNY | 5.08億 CNY |
| 売上原価 | 1.37億 CNY | 1.53億 CNY | 1.74億 CNY | 1.83億 CNY | 1.44億 CNY |
| 粗利益 | 4.03億 CNY | 3.62億 CNY | 3.63億 CNY | 3.8億 CNY | 3.64億 CNY |
| 研究開発 | 1.66億 CNY | 2.32億 CNY | 3.47億 CNY | 4.22億 CNY | 3.68億 CNY |
| 販売・一般管理 | 2.91億 CNY | 4.53億 CNY | 6.86億 CNY | 9.39億 CNY | 7.93億 CNY |
| 営業費用 | 4.58億 CNY | 7.2億 CNY | 10.33億 CNY | 13.6億 CNY | 11.61億 CNY |
| 受取利息 | 805.3万 CNY | 1221.2万 CNY | 1795.6万 CNY | 945.8万 CNY | 345.7万 CNY |
| 支払利息 | 3万 CNY | — | — | — | 153.6万 CNY |
| 減価償却費と償却費 | 2176.1万 CNY | 5220万 CNY | 1.33億 CNY | 1.24億 CNY | 4776.6万 CNY |
| 営業利益 | −5484.5万 CNY | −3.58億 CNY | −6.69億 CNY | −9.8億 CNY | −7.97億 CNY |
| 純利益 | −5534.6万 CNY | −3.47億 CNY | −6.54億 CNY | −9.71億 CNY | −7.97億 CNY |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2024年5月15日 | 1:10 | — | — |
株式分割 | 2014年8月1日 | 1:3 | — | — |
発効済み 2024年5月15日
1:10
発効済み 2014年8月1日
1:3
この株式へのエクスポージャーを報告している上場投資信託です。
Schwab International Equity ETFSCHF1906.77万0.03%673.48億 USD0.03%$27.14+0.04%
Schwab Fundamental International Large Company Index ETFFNDF1792.53万0.07%253.12億 USD0.25%$53.73+0.58%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1309.38万0.03%406.96億 USD0.03%$49.78+0.19%
State Street SPDR Portfolio Europe ETFSPEU35.16万0.05%6.89億 USD0.07%$53.35+0.62%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA26.22万0.03%10.17億 USD0.30%$97.99+0.48%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX20.17万0.04%4.88億 USD0.20%$53.34+0.41%
State Street SPDR MSCI World StrategicFactors ETFQWLD1.44万0.01%1.76億 USD0.30%$156.680.00%Schwab International Equity ETFSCHFSchwab Fundamental International Large Company Index ETFFNDFState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXState Street SPDR MSCI World StrategicFactors ETFQWLDAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
